Vanderbilt Autonomic Dysfunction Center, Division of Clinical Pharmacology, Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN, USA.
Hypertension. 2012 Mar;59(3):650-6. doi: 10.1161/HYPERTENSIONAHA.111.184812. Epub 2012 Feb 6.
Patients with autonomic failure have disabling orthostatic hypotension because of impaired sympathetic activity. Norepinephrine transporter blockade with atomoxetine raises blood pressure in autonomic failure by increasing synaptic norepinephrine concentrations in postganglionic sympathetic neurons. This effect requires tonic release of norepinephrine, which is decreased in patients with low sympathetic tone. We hypothesized that increasing residual sympathetic outflow with the α-2 antagonist yohimbine would potentiate the pressor effect of norepinephrine transporter blockade with atomoxetine and improve orthostatic tolerance in peripheral autonomic failure. Seventeen patients received a single oral dose of either placebo, yohimbine 5.4 mg or atomoxetine 18.0 mg, and the combination yohimbine and atomoxetine in a single blind, crossover study. Blood pressure was assessed while patients were seated and standing for ≤10 minutes before and 1 hour postdrug. Neither yohimbine nor atomoxetine significantly increased seated systolic blood pressure or orthostatic tolerance compared with placebo. The combination, however, significantly increased seated systolic blood pressure and orthostatic tolerance (P<0.001 and P=0.016, respectively) in a synergistic manner. The maximal increase in seated systolic blood pressure seen with the combination was 31±33 mm Hg at 60 minutes postdrug. Only the combination showed a significant improvement in orthostatic symptoms. In conclusion, the combination of yohimbine and atomoxetine had a synergistic effect on blood pressure and orthostatic tolerance in peripheral autonomic failure, which may be explained by an increased release of norepinephrine in peripheral sympathetic neurons by α-2 antagonism combined with a reduced norepinephrine clearance by norepinephrine transporter blockade. Safety studies are required to address the clinical usefulness of this pharmacological approach.
患有自主神经功能衰竭的患者由于交感活动受损而出现体位性低血压。通过增加节后交感神经元突触去甲肾上腺素浓度,托莫西汀阻断去甲肾上腺素转运体可升高自主神经衰竭患者的血压。这种作用需要去甲肾上腺素的持续释放,而在交感神经张力低的患者中,去甲肾上腺素的释放减少。我们假设,用α-2 拮抗剂育亨宾增加残留的交感神经输出,会增强托莫西汀对去甲肾上腺素转运体的阻断作用,并改善外周自主神经衰竭的体位耐受力。17 名患者接受了单剂量的安慰剂、育亨宾 5.4mg 或托莫西汀 18.0mg,以及育亨宾和托莫西汀的组合,采用单盲交叉研究。在给药前和给药后 1 小时,评估患者在坐位和站立位时的血压,持续时间≤10 分钟。与安慰剂相比,育亨宾和托莫西汀均未显著增加坐位收缩压或体位耐受力。然而,联合用药以协同方式显著增加了坐位收缩压和体位耐受力(分别为 P<0.001 和 P=0.016)。联合用药后 60 分钟,坐位收缩压的最大增加为 31±33mmHg。只有联合用药显示出对体位症状的显著改善。总之,育亨宾和托莫西汀的联合用药对周围自主神经衰竭患者的血压和体位耐受力有协同作用,这可能是由于α-2 拮抗作用增加了外周交感神经元中去甲肾上腺素的释放,同时减少了去甲肾上腺素转运体的清除。需要进行安全性研究来确定这种药理学方法的临床应用价值。